CLINICAL TRIALS PROFILE FOR ZYRTEC HIVES

505(b)(2) Clinical Trials for ZYRTEC HIVES

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT02024152 ↗	Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg	Completed	Algorithme Pharma Inc	Phase 1	2011-03-01	This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
OTC	NCT02024152 ↗	Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg	Completed	JDP Therapeutics, Inc.	Phase 1	2011-03-01	This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
OTC	NCT02865018 ↗	Neuromyelitis Optica (NMO) & Cetirizine	Completed	Guthy Jackson Charitable Foundation	Phase 1/Phase 2	2014-04-01	Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability. Without treatment, within 5 years 50% of NMO patients are blind in one or both eyes or require walking assistance (cane, walker or wheelchair). NMO has only been relatively recently described and is fairly rare. Most NMO patients' immune systems produce abnormal antibodies against aquaporin-4 (AQP4), which is found in certain cells in the central nervous system. When these AQP4 antibodies bind to AQP4, they trigger a cascade of events involving the immune system which eventually leads to damage to the nervous system. This ultimately leads to disability, some of which is permanent. Until now, treatments for NMO have been mostly focused on decreasing production of this AQP4 antibody. However, recent experiments in animal models of NMO have shown the importance of what happens inside the central nervous system after the antibody binds to the nervous system cell. Specifically, researchers have noted the importance of a specific cell type, eosinophils, in causing damage in NMO lesions. In a recent study, researchers showed they could prevent damage from NMO by blocking eosinophils using cetirizine, which is a popular over-the-counter allergy medicine. Cetirizine is already known to be safe and well-tolerated in the general population. In this study, the researchers plan to add cetirizine on to patients' current NMO treatment. The researchers aim to show that it is safe, well-tolerated, and that with cetirizine, NMO patients have less relapses and therefore less disability over the course of the year following initiation of treatment. The researchers also plan to study how cetirizine changes the immunological profile in NMO patients by examining blood and cerebrospinal fluid.

All Clinical Trials for ZYRTEC HIVES

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00240032 ↗	A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 4	2004-10-01	This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections. Patients will be assigned (like a flip of a coin) to take either a placebo or an antihistamine (Zyrtec®) prior to performing their daily Copaxone® injections. The patient and physician will be unaware whether they are taking a placebo or antihistamine during the study.
NCT00240032 ↗	A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.	Completed	Teva Pharmaceutical Industries	Phase 4	2004-10-01	This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections. Patients will be assigned (like a flip of a coin) to take either a placebo or an antihistamine (Zyrtec®) prior to performing their daily Copaxone® injections. The patient and physician will be unaware whether they are taking a placebo or antihistamine during the study.
NCT00375713 ↗	Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema	Completed	UCB Pharma	Phase 3	2005-10-01	Korean double-blind non-inferiority study to asses the efficacy (as measured by the responder rate of pruritus severity score by the patient at visit 4 or end-of-treatment visit over the 2 weeks treatment period) and safety of Xyzal® to Zyrtec® in subjects suffering from dermatitis and eczema with pruritus symptoms

Clinical Trial Conditions for ZYRTEC HIVES

Condition Name

Condition Name for ZYRTEC HIVES
Intervention	Trials
Healthy	6
Allergic Rhinitis	6
Seasonal Allergic Rhinitis	5

Condition MeSH

Condition MeSH for ZYRTEC HIVES
Intervention	Trials
Rhinitis	13
Rhinitis, Allergic	12
Rhinitis, Allergic, Seasonal	6

Clinical Trial Locations for ZYRTEC HIVES

Trials by Country

Trials by Country for ZYRTEC HIVES
Location	Trials
United States	13
Canada	3
Austria	1
Korea, Republic of	1

Trials by US State

Trials by US State for ZYRTEC HIVES
Location	Trials
Maryland	3
Texas	3
Georgia	1
Indiana	1
Illinois	1

Clinical Trial Progress for ZYRTEC HIVES

Clinical Trial Phase

Clinical Trial Phase for ZYRTEC HIVES
Clinical Trial Phase	Trials
Phase 4	12
Phase 3	5
Phase 2	1

Clinical Trial Status

Clinical Trial Status for ZYRTEC HIVES
Clinical Trial Phase	Trials
Completed	27
Recruiting	1
Terminated	1

Clinical Trial Sponsors for ZYRTEC HIVES

Sponsor Name

Sponsor Name for ZYRTEC HIVES
Sponsor	Trials
Merck Sharp & Dohme Corp.	7
Faes Farma, S.A.	3
Mylan Pharmaceuticals	2

Sponsor Type

Sponsor Type for ZYRTEC HIVES
Sponsor	Trials
Industry	28
Other	12
NIH	2

ZYRTEC HIVES Market Analysis and Financial Projection

Last updated: April 27, 2026

ZYRTEC HIVES (cetirizine hydrochloride) clinical trials update, market analysis, and projection

What is “ZYRTEC HIVES” in product terms?

“ZYRTEC HIVES” is a branded over-the-counter (OTC) antihistamine regimen built around cetirizine hydrochloride for the symptomatic treatment of hives (urticaria). ZYRTEC is the U.S.-market brand; the active ingredient is cetirizine.

What does the clinical evidence base look like for cetirizine in hives?

Cetirizine is supported by a mature clinical evidence base for chronic spontaneous urticaria (CSU) and acute urticaria/inducible urticaria symptom control, including placebo-controlled trials and guideline-consistent dosing studies. The current state of play for a market monitoring view is that cetirizine is not in an “emergent late-stage pipeline” cycle; it is in an established efficacy and safety position with ongoing label refinement rather than new pivotal programs.

Practical implication for investors and R&D:

• The competitive differentiation in “hives” is less about novel mechanism and more about formulation, dosing convenience, speed of symptom relief claims, and OTC access.
• For cetirizine-based brands, new trials tend to be label updates, bioequivalence, pediatric bridging, or formulation work, not mechanism breakthroughs.

What is the current clinical-trials update posture (2020 to 2026) for cetirizine/urticaria?

Across the period, the dominant clinical-trials footprint for cetirizine in urticaria is:

• Randomized efficacy studies in CSU and inducible urticaria that are primarily confirmatory relative to earlier pivotal datasets.
• Safety monitoring and real-world effectiveness publications rather than new, registry-defining Phase 3 programs.
• OTC-relevant programs such as pediatric labeling support and formulation optimization.

Given the drug’s maturity, the most actionable clinical-trials update for market decisions is not the emergence of new efficacy assets but the persistence of guideline use and the stability of the safety profile in routine care.

---

How big is the “hives” OTC antihistamine market and how does cetirizine compete?

What is the market frame for OTC hives treatment?

The commercial “hives” universe is a subset of the broader OTC allergy/antihistamine market. It splits by:

• Class: second-generation H1 antihistamines (including cetirizine, loratadine, fexofenadine)
• Channel: mass retail, pharmacy chains, e-commerce, subscription
• Form: tablets, dissolvable, liquid, gelcaps, children’s formulations
• Positioning: “non-drowsy” claims (relative), 24-hour coverage, dosing frequency, speed claims

Cetirizine typically competes strongly on:

• Perceived efficacy (CSU symptom control) versus older antihistamines
• Dosing convenience (once daily OTC regimens)
• Broadness of patient fit (adults and children formulations)

Where does cetirizine sit versus key OTC competitors?

Key competitor set in antihistamines for allergic conditions and urticaria symptom control includes:

• Loratadine
• Fexofenadine
• Levocetirizine
• Diphenhydramine and other first-generation agents (price/availability, but drowsiness burden)

Competitive dynamics:

• Cetirizine has a strong OTC footprint and brand equity.
• Fexofenadine is often advantaged in marketing for “non-drowsy” positioning.
• Loratadine and levocetirizine compete on dosing convenience and “less drowsy” positioning.
• Price pressure is ongoing from generics and private label, especially on tablets and liquids.

---

What is the revenue and demand outlook for cetirizine brands in hives (2025–2030)?

What demand drivers support growth or resilience?

For ZYRTEC HIVES (cetirizine), demand drivers are structural:

1. Chronic and recurrent urticaria prevalence in the consumer base seeking symptom relief.
2. OTC accessibility and entrenched use among households with seasonal and episodic allergy triggers.
3. Switching inertia: once a household finds acceptable efficacy and tolerability, repeat purchase behavior is stable.
4. Channel expansion: e-commerce visibility and subscription bundles sustain baseline volume.

What are the main headwinds?

1. Generic substitution on cetirizine tablets (the active ingredient is commoditized).
2. “Non-drowsy” brand messaging competition (especially fexofenadine and loratadine centric portfolios).
3. Regulatory and consumer scrutiny of pediatric and long-term self-medication claims (managed through label conservatism rather than trial innovation).

Market projection (directional)

Because cetirizine is mature and the active ingredient is widely generic, the projection profile for ZYRTEC HIVES is typically:

• Volume: stable to low-single-digit growth, driven by category expansion and channel shift
• Value: modest growth, constrained by generic price pressure, offset by brand, pack mix, and formulation premiums

Directional projection band (OTC hives within antihistamines)

• 2025–2027: low to mid-single-digit category value growth; brand value growth lags category when promotions intensify
• 2028–2030: steady-state growth with periodic supply, pack-size optimization, and higher-margin formulations supporting incremental value gains

Strategic read-through:

• The highest upside is not new clinical assets but retail execution (pack mix, bundling, seasonal merchandising), plus label-consistent claims that keep the brand competitive in urticaria symptom management.

---

What is the patent and exclusivity posture impacting commercialization?

For established OTC actives like cetirizine, patent life and exclusivity dynamics generally favor:

• The original innovators at launch period
• Then widespread generic availability that makes pricing the key variable
• Brand differentiation through marketing and formulation rather than monopoly pricing

For investment and R&D planning, the practical conclusion is that near-term commercialization is not bottlenecked by new cetirizine patent filings for hives; it is bottlenecked by brand economics, generic competition, and channel share.

---

Key product and trial implications for business decisions

If you are evaluating competitive entry or brand expansion, what matters most?

1. Form factor and dosing convenience (tablets vs dissolvable vs liquid)
2. Shelf value economics (promotional intensity, pack sizes, multipacks)
3. Consumer perception: tolerability and onset messaging
4. Compliance with labeling and OTC advertising rules for urticaria symptom claims

If you are planning new clinical work for urticaria, where does it fit?

For a cetirizine-based portfolio, the likely “clinical” work that creates measurable business outcomes is:

• Bioequivalence and formulation bridging to expand OTC SKU count
• Pediatric access and labeling alignment
• Real-world outcome studies that support marketing claims without re-running pivotal Phase 3 programs

---

Key Takeaways

• ZYRTEC HIVES is cetirizine-based OTC symptomatic therapy for hives/urticaria with a mature clinical evidence base and stable guideline positioning.
• The clinical-trials update posture is confirmatory and label/pediatric/formulation oriented, not a pivot to new late-stage efficacy assets.
• Market growth for “hives” is constrained by generic substitution; brand upside comes from pack mix, channel execution, and formulation SKU premiums.
• From 2025 to 2030, the outlook is stable to low growth in volume with modest value growth, driven by brand economics rather than novelty.

---

FAQs

1) Does cetirizine have Phase 3 urticaria breakthroughs driving new demand?

The current market reality is that cetirizine’s urticaria role is established, so recent activity is mostly confirmatory and labeling/formulation oriented rather than a new Phase 3 pivot that would reset demand curves.

2) What competitive class pressures most affect ZYRTEC HIVES pricing?

Generic cetirizine substitution and competing second-generation OTC antihistamines (notably fexofenadine and loratadine positioning) drive promotional and pricing pressure.

3) What product levers most influence OTC hives share?

Pack mix, dosage convenience (including pediatric-ready formats), distribution coverage, and promotional calendar alignment to seasonal and event-driven peaks.

4) Is the market for hives distinct from general OTC allergy demand?

It overlaps, but “hives” is a targeted symptom state that draws buyers from allergy and dermatology-adjacent needs. It benefits from household repeat purchase when efficacy and tolerability are perceived as reliable.

5) Where can clinical work create the most business value for a mature OTC active?

Bioequivalence/formulation expansion, pediatric or SKU bridging, and real-world effectiveness studies that support label-consistent marketing claims.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Drug approvals and databases (label and review resources for antihistamines and cetirizine products). https://www.fda.gov/drugs
[2] National Library of Medicine. (n.d.). ClinicalTrials.gov (search: cetirizine urticaria/chronic spontaneous urticaria). https://clinicaltrials.gov
[3] American Academy of Allergy, Asthma & Immunology. (n.d.). Guidance and summaries on urticaria management and antihistamine use. https://www.aaaai.org
[4] European Academy of Allergy and Clinical Immunology. (n.d.). Urticaria management guidance and antihistamine positioning. https://www.eaaci.org
[5] National Institute for Health and Care Excellence. (n.d.). Urticaria guidance on antihistamines and management approaches. https://www.nice.org.uk